HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Dura Medical, a revenue-generating and EBITDA-positive interventional psychiatry clinic on Florida's west coast. This acquisition, combined with the previously announced Neurospa TMS network, will expand HOPE's comprehensive mental health services in Florida.
Dura Medical, founded in 2018, specializes in treating mental health and chronic pain using advanced interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato®, and Stellate Ganglion Blocks. The clinic serves both civilian and veteran patients through the Veterans Affairs Community Cares Network.
Stephen Durand, Dura's founder and a US Army Reserve Veteran, will serve as Director of Florida Clinic Operations for HOPE. Dura Medical aims to treat more than 10,000 people by 2026. The acquisition's closing is pending financial audits, regulatory approvals, and standard closing conditions.
HOPE Therapeutics, una filiale interamente posseduta di NRx Pharmaceuticals (NASDAQ:NRXP), ha firmato un accordo definitivo per acquisire Dura Medical, una clinica di psichiatria interventistica generatrice di entrate e positiva in EBITDA sulla costa occidentale della Florida. Questa acquisizione, insieme alla rete Neurospa TMS precedentemente annunciata, espanderà i servizi completi di salute mentale di HOPE in Florida.
Dura Medical, fondata nel 2018, si specializza nel trattamento della salute mentale e del dolore cronico utilizzando procedure avanzate di psichiatria interventistica, tra cui Terapia con Infusione di Ketamina, Stimolazione Magnetica Transcranica (TMS), Spravato® e Blocchi del Ganglio Stellato. La clinica serve sia pazienti civili che veterani attraverso la Rete di Assistenza della Comunità per i Veterani.
Stephen Durand, fondatore di Dura e veterano della Riserva dell'Esercito degli Stati Uniti, sarà il Direttore delle Operazioni della Clinica in Florida per HOPE. Dura Medical punta a trattare più di 10.000 persone entro il 2026. La chiusura dell'acquisizione è in attesa di audit finanziari, approvazioni normative e condizioni standard di chiusura.
HOPE Therapeutics, una subsidiaria de propiedad total de NRx Pharmaceuticals (NASDAQ:NRXP), ha firmado un acuerdo definitivo para adquirir Dura Medical, una clínica de psiquiatría intervencionista generadora de ingresos y positiva en EBITDA en la costa oeste de Florida. Esta adquisición, combinada con la red Neurospa TMS anunciada previamente, expandirá los servicios integrales de salud mental de HOPE en Florida.
Dura Medical, fundada en 2018, se especializa en el tratamiento de la salud mental y el dolor crónico utilizando procedimientos avanzados de psiquiatría intervencionista, incluyendo Terapia de Infusión de Ketamina, Estimulación Magnética Transcraneal (TMS), Spravato® y Bloqueos del Ganglio Estrellado. La clínica atiende tanto a pacientes civiles como a veteranos a través de la Red de Cuidado Comunitario de Asuntos de Veteranos.
Stephen Durand, fundador de Dura y veterano de la Reserva del Ejército de EE. UU., será el Director de Operaciones de la Clínica de Florida para HOPE. Dura Medical tiene como objetivo tratar a más de 10,000 personas para 2026. El cierre de la adquisición está pendiente de auditorías financieras, aprobaciones regulatorias y condiciones estándar de cierre.
HOPE Therapeutics는 NRx Pharmaceuticals (NASDAQ:NRXP)의 완전 자회사로, 플로리다 서부 해안에 위치한 수익을 창출하고 EBITDA가 긍정적인 개입 정신의학 클리닉인 Dura Medical 인수를 위한 최종 계약을 체결했습니다. 이 인수는 이전에 발표된 Neurospa TMS 네트워크와 결합하여 플로리다에서 HOPE의 포괄적인 정신 건강 서비스를 확장할 것입니다.
2018년에 설립된 Dura Medical은 케타민 주입 요법, 경두개 자기 자극 (TMS), Spravato® 및 별자리 신경 차단을 포함한 고급 개입 정신의학 절차를 사용하여 정신 건강과 만성 통증을 치료하는 데 전문화되어 있습니다. 이 클리닉은 재향 군인 관리국의 지역 사회 관리 네트워크를 통해 민간인 및 재향 군인 환자를 모두 치료합니다.
Dura의 창립자이자 미국 육군 예비군 재향 군인인 Stephen Durand는 HOPE의 플로리다 클리닉 운영 이사로 일할 것입니다. Dura Medical은 2026년까지 10,000명 이상의 사람들을 치료하는 것을 목표로 하고 있습니다. 인수 마감은 재무 감사, 규제 승인 및 표준 마감 조건을 기다리고 있습니다.
HOPE Therapeutics, une filiale entièrement détenue de NRx Pharmaceuticals (NASDAQ:NRXP), a signé un accord définitif pour acquérir Dura Medical, une clinique de psychiatrie interventionnelle génératrice de revenus et positive en EBITDA sur la côte ouest de la Floride. Cette acquisition, combinée au réseau Neurospa TMS précédemment annoncé, viendra élargir les services complets de santé mentale de HOPE en Floride.
Dura Medical, fondée en 2018, se spécialise dans le traitement des problèmes de santé mentale et de la douleur chronique en utilisant des procédures avancées de psychiatrie interventionnelle, y compris Thérapie par Infusion de Kétamine, Stimulation Magnétique Transcrânienne (TMS), Spravato® et Blocages du Ganglion Étoilé. La clinique sert à la fois des patients civils et des vétérans par le biais du Réseau de Soins Communautaires des Anciens Combattants.
Stephen Durand, fondateur de Dura et vétéran de la Réserve de l'Armée des États-Unis, sera le Directeur des Opérations de la Clinique de Floride pour HOPE. Dura Medical vise à traiter plus de 10 000 personnes d'ici 2026. La clôture de l'acquisition est en attente d'audits financiers, d'approbations réglementaires et de conditions de clôture standard.
HOPE Therapeutics, eine hundertprozentige Tochtergesellschaft von NRx Pharmaceuticals (NASDAQ:NRXP), hat einen endgültigen Vertrag zur Übernahme von Dura Medical unterzeichnet, einer umsatzgenerierenden und EBITDA-positiven Klinik für interventionelle Psychiatrie an der Westküste Floridas. Diese Übernahme, zusammen mit dem zuvor angekündigten Neurospa TMS-Netzwerk, wird die umfassenden psychischen Gesundheitsdienste von HOPE in Florida erweitern.
Dura Medical, 2018 gegründet, hat sich auf die Behandlung von psychischen Erkrankungen und chronischen Schmerzen spezialisiert und nutzt dabei fortschrittliche interventionelle psychiatrische Verfahren, darunter Ketamin-Infusionstherapie, Transkranielle Magnetstimulation (TMS), Spravato® und stellatganglionäre Blockaden. Die Klinik betreut sowohl zivile als auch veteranische Patienten über das Netzwerk der Gemeinschaftspflege des Veteranenministeriums.
Stephen Durand, der Gründer von Dura und Veteran der US-Armee, wird als Direktor der Klinikbetriebe in Florida für HOPE tätig sein. Dura Medical hat das Ziel, bis 2026 mehr als 10.000 Menschen zu behandeln. Der Abschluss der Übernahme steht noch aus und hängt von finanziellen Prüfungen, behördlichen Genehmigungen und den üblichen Abschlussbedingungen ab.
- Revenue-generating and EBITDA-positive acquisition target
- Expansion of service coverage throughout Florida's west coast
- Access to VA Community Cares Network contract
- Clear growth target of 10,000 patients by 2026
- Complementary integration with previously announced Neurospa network
- Acquisition still subject to financial audits and regulatory approvals
- Integration costs and timeline not disclosed
- Purchase price and financial terms not revealed
Insights
This acquisition represents a strategic pivot for micro-cap NRx Pharmaceuticals, expanding beyond pharmaceutical development into the mental health services sector. The acquisition of revenue-generating and EBITDA-positive Dura Medical could provide immediate financial benefits for a company with only
By acquiring both Dura Medical and the previously announced Neurospa TMS, NRx is establishing a comprehensive mental health treatment network across Florida's west coast. This expansion provides operational scale and potential synergies in marketing, staffing, and administrative functions. The strategic importance extends beyond immediate financials - it gives NRx diversified revenue streams through both private insurance and government contracts via Dura's existing Veterans Affairs relationship.
For NRXP investors, this shift toward cash-flow positive clinical operations could reduce capital market dependency while the company pursues its pharmaceutical pipeline. The interventional psychiatry market offers recurring revenue potential from conditions requiring ongoing treatment. However, this diversification introduces new operational complexities for management, requiring expertise in clinical service delivery different from drug development.
The acquisition of Dura Medical positions NRx strategically in the growing interventional psychiatry space, which addresses treatment-resistant mental health conditions through advanced modalities. Dura's comprehensive service offering - including Ketamine Therapy, Transcranial Magnetic Stimulation (TMS), Spravato®, and Stellate Ganglion Blocks - represents the cutting edge of non-pharmaceutical approaches to severe depression, PTSD, and suicidality.
Particularly valuable is Dura's established relationship with the Veterans Affairs Community Cares Network, providing access to a patient population with high rates of treatment-resistant conditions. Veterans represent both a stable referral source and an underserved population for mental health innovations. Retaining founder Stephen Durand ensures operational continuity and specialized expertise in veteran care.
The combined capabilities of Dura and the previously announced Neurospa acquisition creates a more robust clinical network able to provide comprehensive care pathways. This integrated approach aligns with current mental health treatment trends emphasizing multimodal interventions rather than standalone therapies. With Dura's founder stating an ambitious goal to "treat more than 10,000 people by 2026," the acquisition provides NRx with established infrastructure and operational expertise in a specialized niche that commands higher reimbursement rates than traditional psychiatric services.
- Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of
Florida - Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients
- Stephen Durand, founder of Dura, to serve as Director of Clinic Operations for HOPE in
Florida
Dura Medical was founded in 2018 to offer a gold-standard, precision approach to treating mental health and chronic pain on the west coast of Florida. The clinics leverage the latest interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato® and Stellate Ganglion Blocks, augmented by traditional psychiatry and therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders.
A US Army Reserve Veteran, Mr. Durand and Dura Medical are proud to provide for the Veterans Affairs Community Cares Network (VA CCN) under an agreement with the US Department of Veterans Affairs to ensure that military veterans have full access to Ketamine Infusion Therapy, TMS and Spravato®, in addition to Traumatic Incident Reduction Therapy (TIR).
In conjunction with the planned acquisition, HOPE is honored to appoint Mr. Durand as Director of Florida Clinic Operations.
"We founded Dura Medical with the mission to reduce suicide in our community and aim to treat more than 10,000 people by 2026. We're excited to align mission with the HOPE Network and to lead HOPE's expansion in
"Steve Durand has been a pioneer in combining the use of psychedelic medications with neuroplastic technologies, including TMS in the treatment of suicidal depression and PTSD. We are excited to incorporate Dura's tradition of excellence and commitment to patient care for civilians and veterans alike into HOPE's
The intended closing of the of Dura acquisition is subject to completion of financial audits, regulatory approvals, and the satisfaction of standard closing conditions.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company currently developing a best-in-class network of interventional psychiatry clinics to offer psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other lifesaving, neuroplastic therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under data sharing agreements. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
Chief Business Officer, NRx Pharmaceuticals, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-definitive-purchase-agreement-with-dura-medical-initial-acquisition-for-planned-international-network-of-interventional-psychiatry-clinics-302415522.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What services will NRXP's HOPE Therapeutics offer through the Dura Medical acquisition?
How many patients does Dura Medical plan to treat by 2026 under NRXP ownership?
What is the current financial status of Dura Medical being acquired by NRXP?
How will NRXP's acquisition of Dura Medical benefit veterans?
What conditions need to be met for NRXP to complete the Dura Medical acquisition?
